|
Enhancing clinical trial screening with a comprehensive large language model platform. |
| |
|
Honoraria - Clarified Precision Medicine; VieCure |
Consulting or Advisory Role - Clarified Precision Medicine; VieCure |
Research Funding - American Association for Cancer Research (Inst); Bristol-Myers Squibb (Inst); Professional Compounding Centers of America (Inst); Symberix (Inst); WinSanTor (Inst) |
| |
|
|
|
Stock and Other Ownership Interests - LindAI |
Patents, Royalties, Other Intellectual Property - I receive ~$40/quarter of royalties for the sale of the Galleri multi-cancer early detection test from GRAIL |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Dexcom; Lilly; Merck; Tempus |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - LindAI |
| |
|
|
Stock and Other Ownership Interests - LindAI |
| |
|
|
Stock and Other Ownership Interests - LindAI |
| |
|
|
Stock and Other Ownership Interests - Lind AI |
| |
|
Employment - Betteromics; Lind AI |
Leadership - Betteromics; Lind AI |
Stock and Other Ownership Interests - Betteromics; Lind AI |
| |
|
Employment - Lind; National Cancer Institute |
Consulting or Advisory Role - chAIron; Lind |
Other Relationship - Reagan-Udall Foundation for FDA |
(OPTIONAL) Uncompensated Relationships - Duke Margolis |
| |
|
Stock and Other Ownership Interests - Enspectra Health |
Consulting or Advisory Role - Enspectra Health; Veriskin |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |